Search Result

Results for "

Tumor associated macrophages

" in MedChemExpress (MCE) Product Catalog:

By Targets:	TNF Receptor (1) Apoptosis (2) c-Fms (2) Complement System (2) Epigenetic Reader Domain (2) HDAC (1) HSP (1) Liposome (4) NO Synthase (1) PROTACs (1) TGF-β Receptor (1) Toll-like Receptor (TLR) (1) YAP (1)
By Research Areas:	Cancer (19) Inflammation/Immunology (3)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Targets Recommended: TNF Receptor BRK Macrophage migration inhibitory factor (MIF)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99746

Murlentamab 3C23K; GM102	TGF-β Receptor	Inflammation/Immunology Cancer
Murlentamab (3C23K; GM102) is a humanized anti-AMHRII antibody. AMHRII is the anti-Müllerian hormone receptor. Murlentama significantly promotes macrophage-mediated antibody-dependent cell-mediated cytotoxicity (ADCC). Murlentama stimulates pro-inflammatory and anti-tumor internal environment, recruits and activates T cells. Murlentama suppresses tumors growth by inducing naïve macrophage orientation and promoting tumor-associated macrophage (TAM) reprogramming .

HY-15701B

ADH-503 1 Publications Verification (Z)-Leukadherin-1 choline	Complement System	Cancer
ADH-503 ((Z)-Leukadherin-1 choline) is an orally active and allosteric CD11b agonist. ADH-503 leads to the repolarization of tumor-associated macrophages, reduction in the number of tumor-infiltrating immunosuppressive myeloid cells, and enhances dendritic cell responses .

HY-15701A

(Z)-Leukadherin-1 1 Publications Verification ADH-503 free base	Complement System	Cancer
(Z)-Leukadherin-1 (ADH-503 free base) is an orally active and allosteric CD11b agonist. (Z)-Leukadherin-1 leads to the repolarization of tumor-associated macrophages, reduction in the number of tumor-infiltrating immunosuppressive myeloid cells, and enhances dendritic cell responses .

HY-163642

TNF-α agonistic 1	Others	Cancer
TNF-α agonistic 1 (compound 22a) can repolarize tumor-associated macrophages (TAMs) in the tumor microenvironment (TME) from the M2 phenotype to the M1 anti-tumor phenotype .

HY-P10894

mUNO	Epigenetic Reader Domain	Cancer
mUNO is a tumor-homing peptide (mUNO, sequence: "CSPGAK") that specifically binds to mouse CD206, targeting tumor-associated macrophages that express CD206/MRC1. mUNO can interact with human recombinant CD206 .

HY-172271

DSPE-PEG1000-LyP-1	Liposome	Cancer
DSPE-PEG1000-LyP-1 is a PEG compound which composed of DSPE and a nine residue peptide (LyP-1) (HY-P2526). LyP-1 targets tumor-associated lymphatic vessels and macrophages .

HY-172271A

DSPE-PEG2000-LyP-1	Liposome	Cancer
DSPE-PEG2000-LyP-1 is a PEG compound which composed of DSPE and a nine residue peptide (LyP-1) (HY-P2526). LyP-1 targets tumor-associated lymphatic vessels and macrophages .

HY-172271B

DSPE-PEG3000-LyP-1	Liposome	Cancer
DSPE-PEG3000-LyP-1 is a PEG compound which composed of DSPE and a nine residue peptide (LyP-1) (HY-P2526). LyP-1 targets tumor-associated lymphatic vessels and macrophages .

HY-172271C

DSPE-PEG3400-LyP-1	Liposome	Cancer
DSPE-PEG3400-LyP-1 is a PEG compound which composed of DSPE and a nine residue peptide (LyP-1) (HY-P2526). LyP-1 targets tumor-associated lymphatic vessels and macrophages .

HY-128776

Antitumor agent-19	TNF Receptor	Cancer
Antitumor agent-19 is an antitumor agent that targets tumor-associated macrophages (TAMs) and can be used as a potent TAMs modulator. Antitumor agent-19 can increase TNF-alpha levels in tumor cells with EC₅₀ values???of 17.18 μM and 18.87 μM in RAW 264.7 cells and BMDM cells, respectively .

HY-155176

SP-2-225	HDAC	Cancer
SP-2-225 is a selective HDAC6 inhibitor. SP-2-225 enhance the production of cancer-associated antigens and macrophage antigen cross-presentation to T cells. SP-2-225 reduces the tumor volume in a syngeneic SM1 melanoma model .

HY-162415

CSF1R-IN-22	c-Fms Apoptosis	Cancer
CSF1R-IN-22 (Compound C19) is an orally effective CSF-1R selective inhibitor (IC₅₀<6 nM). CSF1R-IN-22 enhances the secretion of CXCL9 from M2 macrophages, increases CD8 ⁺ T cell infiltration. CSF1R-IN-22 boosts anti-tumor immune responses of anti-PD-1, and induces apoptosis in tumor cells. CSF1R-IN-22 can effectively reprogram M2-like TAMs (tumor-associated macrophages) to the M1 phenotype and reshape the TME by inducing the recruitment of CD8 ⁺ T cells into tumors and reducing the infiltration of immunosuppressive Tregs and MDSCs .

HY-117282

JG-98 Maximum Cited Publications 8 Publications Verification	HSP Apoptosis	Cancer
JG-98, an allosteric heat shock protein 70 (Hsp70) inhibitor, which binds tightly to a conserved site on Hsp70 and disrupts the Hsp70-Bag3 interaction. JG-98 shows anti-cancer activities affecting both cancer cells and tumor-associated macrophages .

HY-P10947

MACTIDE-V	Epigenetic Reader Domain YAP	Cancer
MACTIDE-V is an orally active and selective peptide-drug conjugate targeting CD206. MACTIDE-V delivers Verteporfin (HY-B0146) to CD206 ⁺ tumor-associated macrophages (TAM) to inhibit the YAP/TAZ signaling pathway, prompting YAP exclusion from the nucleus, inducing TAM polarization toward an anti-tumoral phenotype with enhanced phagocytosis and antigen presentation, and boosting T cell infiltration and NK cell activity. MACTIDE-V suppresses primary tumor growth and lung metastasis in triple-negative breast cancer (TNBC) mouse models .

HY-158050

PXB17	c-Fms	Cancer
PXB17 can inhibit CSF1R (IC₅₀ = 1.7 nM) by blocking the activation of PI3K/ AKT/mTORC1 signaling. PXB17 is orally effective. PXB17 significantly inhibits the growth of CRC, improves PD-1 mAb efficacy and reduces tumor recurrence in CRC .

HY-172934

FGT-4	Toll-like Receptor (TLR) NO Synthase PROTACs	Inflammation/Immunology Cancer
FGT-4 is a folate receptor β (FR-β) targeting chimeric molecule. FGT-4 is a TLR7 agonist. FGT-4 facilitates the secretion of iNOS and proinflammatory cytokine IL-6 associated with M1 macrophages and enhances the proliferation of cytotoxic CD8 ⁺ T cells. FGT-4 has anti-tumor activity in the 4T1 breast cancer mouse model. FGT-4 can be used for the study of cancer immunity. (Pink: target protein TLR7/8 agonist 1 ligand (HY-103698); black: linker (HY-172936); blue: FR-β ligand (HY-172935)) .

Cat. No.	Product Name	Type

HY-172271

DSPE-PEG1000-LyP-1	Drug Delivery
DSPE-PEG1000-LyP-1 is a PEG compound which composed of DSPE and a nine residue peptide (LyP-1) (HY-P2526). LyP-1 targets tumor-associated lymphatic vessels and macrophages .

HY-172271A

DSPE-PEG2000-LyP-1	Drug Delivery
DSPE-PEG2000-LyP-1 is a PEG compound which composed of DSPE and a nine residue peptide (LyP-1) (HY-P2526). LyP-1 targets tumor-associated lymphatic vessels and macrophages .

HY-172271B

DSPE-PEG3000-LyP-1	Drug Delivery
DSPE-PEG3000-LyP-1 is a PEG compound which composed of DSPE and a nine residue peptide (LyP-1) (HY-P2526). LyP-1 targets tumor-associated lymphatic vessels and macrophages .

HY-172271C

DSPE-PEG3400-LyP-1	Drug Delivery
DSPE-PEG3400-LyP-1 is a PEG compound which composed of DSPE and a nine residue peptide (LyP-1) (HY-P2526). LyP-1 targets tumor-associated lymphatic vessels and macrophages .

Cat. No.	Product Name	Target	Research Area

HY-P10449

M2 Peptide	Peptides	Cancer
M2 Peptide is a peptide targeting M2-like tumor-associated macrophages (TAMs). M2 Peptide is used to carry drugs or small interfering RNA (siRNA) to promote the repolarization of M2-like macrophages to M1-like macrophages, thereby altering the immunosuppressive state in the tumor microenvironment and enhancing the anti-tumor immune response. M2 Peptide can be used to study the effect of macrophage polarization and how this polarization change affects tumor growth and metastasis .

HY-P10894

mUNO	Epigenetic Reader Domain	Cancer
mUNO is a tumor-homing peptide (mUNO, sequence: "CSPGAK") that specifically binds to mouse CD206, targeting tumor-associated macrophages that express CD206/MRC1. mUNO can interact with human recombinant CD206 .

HY-P10947

MACTIDE-V	Epigenetic Reader Domain YAP	Cancer
MACTIDE-V is an orally active and selective peptide-drug conjugate targeting CD206. MACTIDE-V delivers Verteporfin (HY-B0146) to CD206 ⁺ tumor-associated macrophages (TAM) to inhibit the YAP/TAZ signaling pathway, prompting YAP exclusion from the nucleus, inducing TAM polarization toward an anti-tumoral phenotype with enhanced phagocytosis and antigen presentation, and boosting T cell infiltration and NK cell activity. MACTIDE-V suppresses primary tumor growth and lung metastasis in triple-negative breast cancer (TNBC) mouse models .

Cat. No.	Product Name	Target	Research Area

HY-P99746

Murlentamab 3C23K; GM102	TGF-β Receptor	Inflammation/Immunology Cancer
Murlentamab (3C23K; GM102) is a humanized anti-AMHRII antibody. AMHRII is the anti-Müllerian hormone receptor. Murlentama significantly promotes macrophage-mediated antibody-dependent cell-mediated cytotoxicity (ADCC). Murlentama stimulates pro-inflammatory and anti-tumor internal environment, recruits and activates T cells. Murlentama suppresses tumors growth by inducing naïve macrophage orientation and promoting tumor-associated macrophage (TAM) reprogramming .

HY-P99176

ATG-031 1 Publications Verification	Inhibitory Antibodies	Cancer
ATG-031 is a humanized anti-CD24 monoclonal antibody with high affinity and specificity. ATG-031 interacts with Siglec-10 expressed by tumor-associated macrophages. ATG-031 effectively stimulates macrophage-mediated phagocytosis and induces cancer cell destruction by blocking the anti-phagocytic surface proteins. ATG-031 can be used in the study of haematological malignancies as well as solid tumors. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

HY-P99236

Bexmarilimab FP-1305	Inhibitory Antibodies	Inflammation/Immunology Cancer
Bexmarilimab (FP-1305) is a potent humanized anti-CLEVER-1 IgG4-antibody with an IC₅₀ value of 4.51 nM. Bexmarilimab is capable of inducing a phenotypic M2 to M1 immune switch of tumor-associated macrophages. Bexmarilimab can be used in research of cancer .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.